var data={"title":"Imipenem and cilastatin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Imipenem and cilastatin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6359?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">see &quot;Imipenem and cilastatin: Drug information&quot;</a> and <a href=\"topic.htm?path=imipenem-and-cilastatin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Imipenem and cilastatin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182065\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Primaxin I.V.</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182066\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Imipenem and Cilastatin for Injection;</li>\n      <li>Imipenem and Cilastatin for Injection, USP;</li>\n      <li>Primaxin;</li>\n      <li>RAN-Imipenem-Cilastatin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047840\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Carbapenem</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442616\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage recommendations are based on <b>imipenem</b> component; not the preferred carbapenem for preterm infants due to cilastatin accumulation and possible seizures (Blumer 1996; Freij 1985; <i>Red Book</i> [AAP 2015]; Reed 1990); not recommended for CNS infections</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2015]): IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\" class=\"header-col\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Body Weight</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Postnatal age (days)</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dose</b></p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;1 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;14 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 2 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">25 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">25 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">25 mg/kg/dose every 8 hours</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047832\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">see &quot;Imipenem and cilastatin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage recommendations are based on <b>imipenem</b> component.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection; severe infections</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents: IV: 60 to 100 mg/kg/<b>day</b> divided every 6 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Burkholderia pseudomallei</b></i>\n      <b> (melioidosis):</b> Infants, Children, and Adolescents: IV: Initial: 60 to 100 mg/kg/<b>day</b> divided every 6 to 8 hours for at least 10 days; maximum daily dose: 4,000 mg/<b>day</b>; continue parenteral therapy until clinical improvement, then switch to oral therapy if tolerated and/or appropriate (Currie 2003; White 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Febrile neutropenia, empiric therapy: </b>Limited data available: Children and Adolescents: IV: 60 mg/kg/<b>day</b> divided every 6 hours (Caselli 2012; Erbey 2009; Riikonen 1991); some centers use doses as high as 100 mg/kg/day; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 60 to 100 mg/kg/<b>day</b> divided every 6 hours; maximum dose: 500 mg (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis):</b> Infants, Children, and Adolescents: Intraperitoneal: Continuous: Loading dose: 250 mg per liter of dialysate; maintenance dose: 50 mg per liter (ISPD [Warady 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pulmonary exacerbation, cystic fibrosis:</b> Infants, Children, and Adolescents: IV: 100 mg/kg/<b>day</b> divided every 6 hours; maximum daily dose: 4,000 mg/<b>day</b>; efficacy may be limited due to rapid development of resistance (Doring 2009; Zobell 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: Doses based on <b>imipenem </b>content.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Usual dosage range:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Susceptible bacterial species: </b>500 mg every 6 hours or 1,000 mg every 8 hours (maximum dose: 4,000 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Intermediate susceptibility bacterial species:</b> 1,000 mg every 6 hours (maximum dose: 4,000 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Patient weight &lt;30 kg and impaired renal function (not defined): Use not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following adjustments have been recommended (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 60 to 100 mg/kg/day divided every 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 7 to 13 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer 7.5 to 12.5 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 7.5 to 12.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis (IHD): Dialysis: Moderately dialyzable (20% to 50%): 7.5 to 12.5 mg/kg/dose every 24 hours (administer after hemodialysis on dialysis days)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): 7.5 to 12.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): 7 to 13 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Manufacturer's labeling: Estimation of renal function for the purpose of dosing adjustment should be done using the Cockcroft-Gault formula.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Usual dosing regimen of 500 mg every 6 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;90 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;60 to &lt;90 mL/minute: 400 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;30 to &lt;60 mL/minute: 300 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;15 to &lt;30 mL/minute: 200 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;15 mL/minute: Do not administer imipenem and cilastatin unless hemodialysis is instituted within 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Usual dosing regimen of 1,000 mg every 8 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;90 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;60 to &lt;90 mL/minute: 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;30 to &lt;60 mL/minute: 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;15 to &lt;30 mL/minute: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;15 mL/minute: Do not administer imipenem and cilastatin unless hemodialysis is instituted within 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Usual dosing regimen of 1,000 mg every 6 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;90 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;60 to &lt;90 mL/minute: 750 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;30 to &lt;60 mL/minute: 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;15 to &lt;30 mL/minute: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;15 mL/minute: Do not administer imipenem and cilastatin unless hemodialysis is instituted within 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Moderately dialyzable (20% to 50%): Use the dosing recommendation for patients with a CrCl 15 to &lt;30 mL/minute; administer dose after dialysis session and at intervals timed from the end of that dialysis session <b>or</b> 250 to 500 mg every 12 hours (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVH: Loading dose of 1,000 mg, followed by either 250 mg every 6 hours <b>or</b> 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVHD: Loading dose of 1,000 mg, followed by either 250 mg every 6 hours <b>or</b> 500 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVHDF: Loading dose of 1,000 mg, followed by either 250 mg every 6 hours <b>or</b> 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Data suggest that 500 mg every 8 to 12 hours may provide sufficient time above MIC to cover organisms with MIC values &le;2 mg/L; however, a higher dose of 500 mg every 6 hours is recommended for resistant organisms (particularly <i>Pseudomonas</i> spp) with MIC &ge;4 mg/L or deep-seated infections (Fish 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182043\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, powder for reconstitution: Imipenem 250 mg and cilastatin 250 mg; imipenem 500 mg and cilastatin 500 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Primaxin&reg; I.V.: Imipenem 250 mg and cilastatin 250 mg [contains sodium 18.8 mg (0.8 mEq)]; imipenem 500 mg and cilastatin 500 mg [contains sodium 37.5 mg (1.6 mEq)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182027\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047843\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">IV: Administer by IV intermittent infusion; doses &le;500 mg may be infused over 20 to 30 minutes; doses &gt;500 mg should be infused over 40 to 60 minutes. If nausea and/or vomiting occur during administration, decrease the rate of IV infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182059\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at &lt;25&deg;C (77&deg;F). Reconstituted solution is stable for 4 hours at room temperature or 24 hours when refrigerated at 5&deg;C (41&deg;F). Do not freeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047842\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of documented multidrug-resistant gram-negative infection of the lower respiratory tract, urinary tract, intra-abdominal, gynecologic, bone and joint, septicemias, endocarditis, and skin and skin structure due to organisms proven or suspected to be susceptible to imipenem/cilastatin (FDA approved in all ages); treatment of multiple organism infection in which other agents have an insufficient spectrum of activity or are contraindicated due to toxic potential; therapeutic alternative for treatment of gram-negative sepsis in immunocompromised patients. Has also been used for the treatment of peritonitis in patients with peritoneal catheters and as empiric therapy for febrile neutropenic patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182095\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imipenem may be confused with ertapenem, meropenem</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Primaxin may be confused with Premarin, Primacor</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182092\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Phlebitis, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, gastroenteritis, nausea, oral candidiasis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Oliguria, proteinuria, urine discoloration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Decreased hematocrit (more common in infants and children 3 months to 12 years), decreased hemoglobin, decreased platelet count, eosinophilia, increased hematocrit, neutropenia, thrombocythemia,</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Decreased serum bilirubin, increased serum alkaline phosphatase, increased serum ALT, increased serum AST (more common in infants and children 3 months to 12 years), increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Irritation at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Acute renal failure, agranulocytosis, back pain (thoracic spinal), basophilia, bilirubinuria, bone marrow depression, brain disease, candidiasis, casts in urine, change in prothrombin time, <i>Clostridium difficile</i> associated diarrhea, confusion, cyanosis, decreased serum sodium, dental discoloration, drug fever, dyskinesia, erythema multiforme, hallucination, hearing loss, heartburn, hematuria, hemolytic anemia, hemorrhagic colitis, hepatic failure, hepatitis (including fulminant onset), hyperchloremia, hypersensitivity, hyperventilation, hypotension, increased blood urea nitrogen, increased lactate dehydrogenase, increased serum potassium, increased urinary urobilinogen, injection site infection, jaundice, leukocytosis, leukocyturia, leukopenia, lymphocytosis, myoclonus, neutropenia, pancytopenia, positive direct Coombs' test, pseudomembranous colitis, pseudomonas infection (resistant <i>P. aeruginosa</i>), psychiatric disturbances, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182050\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to imipenem/cilastatin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for carbapenems, penicillins, and cephalosporins is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182031\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders (eg, brain lesions and history of seizures) and adjust dose in renal impairment to avoid drug accumulation, which may increase seizure risk. However, there have been reports of adverse CNS effects in patients who had no recognized or documented underlying CNS disorder or compromised renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Serious hypersensitivity/anaphylactic reactions have been reported, including fatalities; may be more common in patients with a history of sensitivity to multiple allergens. Patients with a history of penicillin hypersensitivity may experience severe hypersensitivity reactions when treated with other beta-lactams; carefully inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other beta-lactams, and other allergens. Serious anaphylactic reactions require immediate discontinuation and supportive care as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with moderate to severe renal dysfunction. Increased seizure risk has been reported in patients with significant renal dysfunction. Do not use in patients with CrCl &le;15 mL/minute unless hemodialysis is instituted within 48 hours. For patients on hemodialysis, use is recommended only when the benefit outweighs the potential risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Valproic acid and derivatives: Carbapenems, including imipenem, may decrease the serum concentration of divalproex sodium/valproic acid increasing the risk of breakthrough seizures. Concurrent use of carbapenem antibiotics with divalproex sodium/valproic acid is generally not recommended. Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional antiseizure medication.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Additional potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Not recommended in pediatric CNS infections due to seizure potential. Not recommended in pediatric patients &lt;30 kg with impaired renal function (no data available).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299512\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182036\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13375&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the neurotoxic effect of Imipenem. Imipenem may decrease the serum concentration of CycloSPORINE (Systemic). Imipenem may increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Imipenem. Specifically, the risk of seizures may be increased. Management: Avoid concomitant use of these agents unless the prospective benefits of therapy outweigh the risks.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Imipenem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Carbapenems may decrease the serum concentration of Valproate Products.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182039\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182052\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Due to pregnancy induced physiologic changes, some pharmacokinetic parameters of imipenem/cilastatin may be altered. Pregnant women have a larger volume of distribution resulting in lower serum peak levels than for the same dose in nonpregnant women. Clearance is also increased.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047839\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic renal, hepatic, and hematologic function tests; bowel movement frequency. Monitor for signs of anaphylaxis during first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182030\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Cilastatin prevents renal metabolism of imipenem by competitive inhibition of dehydropeptidase along the brush border of the renal tubules.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182049\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Imipenem: ~20%; cilastatin: ~40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Imipenem is metabolized in the kidney by dehydropeptidase I; cilastatin prevents imipenem metabolism by this enzyme.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: Both drugs: Prolonged with renal impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: Imipenem: 1.7 to 2.4 hours; Cilastatin: 3.9 to 6.3 hours (Freij 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children: Imipenem: 1.2 hours (Blumer 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Both drugs: Urine (~70% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047847\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium content: 250 mg vial contains 0.8 mEq; 500 mg vial contains 1.6 mEq</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323195\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Imipenem-Cilastatin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $5.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $11.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Primaxin IV Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-250 mg (1): $20.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500-500 mg (1): $39.18</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182054\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anipen (PH);</li>\n      <li>Arzobema (MX);</li>\n      <li>Bacquire (ZW);</li>\n      <li>Bacqure (TH);</li>\n      <li>Bidinam (VN);</li>\n      <li>Bionam (TH);</li>\n      <li>Cilanem (JO);</li>\n      <li>Cilapenem (KR, TH);</li>\n      <li>Cispenam (BD);</li>\n      <li>Haizheng Junte (CN);</li>\n      <li>Imenam (TW);</li>\n      <li>Imicila Alvogen (TH);</li>\n      <li>Imiclast (ID);</li>\n      <li>Iminem (BD);</li>\n      <li>Iminen (MX);</li>\n      <li>Imipen (PH);</li>\n      <li>Imivex (PH);</li>\n      <li>Inem (BD, CL, PY);</li>\n      <li>Minem (TH);</li>\n      <li>Nemcis (VN);</li>\n      <li>Nimedine (MT);</li>\n      <li>Pelascap (ID);</li>\n      <li>Pelastin IV (ID);</li>\n      <li>Penam (PH);</li>\n      <li>Plastin (PH);</li>\n      <li>Premax (JO);</li>\n      <li>Prepenem (HK, KR, PH, TH);</li>\n      <li>Primax (BD);</li>\n      <li>Primaxin (AU, GB, GR, MT, NZ);</li>\n      <li>Primaxin IV (BB, BM, BS, BZ, GY, JM, SR, TT);</li>\n      <li>Sianem (TH);</li>\n      <li>Supernem (TW);</li>\n      <li>Supranem (UA);</li>\n      <li>Talispenem (VN);</li>\n      <li>Tenacid (IT);</li>\n      <li>Tiaktam (UA);</li>\n      <li>Tienam (AE, BD, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DK, DO, EC, EE, EG, ES, ET, FI, FR, GT, HK, HN, HR, ID, IE, IL, IN, IT, JO, JP, KW, LB, LT, LU, LV, MX, MY, NI, NL, NO, PA, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SK, SV, TH, TR, TW, VN);</li>\n      <li>Tiesilan (CO, EC);</li>\n      <li>Timipen (ID);</li>\n      <li>Tipem (KR);</li>\n      <li>Tiyenam (UA);</li>\n      <li>Vexpinem (PH);</li>\n      <li>Xerxes (ID);</li>\n      <li>Zienam (AR, AT, DE, PY, UY, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahonkhai VI, Cyhan GM, Wilson SE, et al, &ldquo;Imipenem-Cilastatin in Pediatric Patients: An Overview of Safety and Efficacy in Studies Conducted in the United States,&rdquo; <i>Pediatr Infect Dis J</i>, 1989, 8(11):740-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/2687787/pubmed\" target=\"_blank\" id=\"2687787\">2687787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer JL, &quot;Pharmacokinetic Determinants of Carbapenem Therapy in Neonates and Children,&quot; <i>Pediatr Infect Dis J</i>, 1996, 15(8):733-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/8858691/pubmed\" target=\"_blank\" id=\"8858691\">8858691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caselli D, Paolicchi O. Empiric antibiotic therapy in a child with cancer and suspected septicemia. <i>Pediatr Rep</i>. 2012;4(1):e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/22690308/pubmed\" target=\"_blank\" id=\"22690308\">22690308</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Currie BJ, &quot;Melioidosis: An Important Cause of Pneumonia in Residents of and Travellers Returned from Endemic Regions,&quot; <i>Eur Respir J</i>, 2003, 22(3):542-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/14516149/pubmed\" target=\"_blank\" id=\"14516149\">14516149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    D&ouml;ring G, Conway SP, Heijerman HG, et al, &quot;Antibiotic Therapy Against <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis: A European Consensus,&quot; <i>Eur Respir J</i>, 2000, 16(4):749-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/11106223/pubmed\" target=\"_blank\" id=\"11106223\">11106223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erbey F, Bayram I, Yilma S, Tanyeli A. Imipenem in the treatment of febrile neutropenic children. <i>Asian Pac J Cancer Prev</i>. 2009;10(5):921-924.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/20104991/pubmed\" target=\"_blank\" id=\"20104991\">20104991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fish DN, Teitelbaum I, and Abraham E, &quot;Pharmacokinetics and Pharmacodynamics of Imipenem During Continuous Renal Replacement Therapy in Critically Ill Patients,&quot; <i>Antimicrob Agents Chemother</i>, 2005, 49(6):2421-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/15917542/pubmed\" target=\"_blank\" id=\"15917542\">15917542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freij BJ, McCracken GH Jr, Olsen KD, et al, &quot;Pharmacokinetics of Imipenem-Cilastatin in Neonates,&quot; <i>Antimicrob Agents Chemother</i>, 1985, 27(4):431-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/3859242/pubmed\" target=\"_blank\" id=\"3859242\">3859242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Overturf GD, &ldquo;Use of Imipenem-Cilastatin in Pediatrics,&rdquo; <i>Pediatr Infect Dis J</i>, 1989, 8(11):792-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/2687788 /pubmed\" target=\"_blank\" id=\"2687788 \">2687788 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Primaxin injection (imipenem and cilastatin) [prescribing information]. WHitehouse Station, NJ: Merck &amp; Co, Inc.; December 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/2687788 /pubmed\" target=\"_blank\" id=\"2687788 \">2687788 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed MD, Kliegman RM, Yamashita TS, et al, &quot;Clinical Pharmacology of Imipenem and Cilastatin in Premature Infants During the First Week of Life,&quot; <i>Antimicrob Agents Chemother</i>, 1990, 34(6):1172-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/2393278/pubmed\" target=\"_blank\" id=\"2393278\">2393278</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riikonen P. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. <i>Pediatr Infect Dis J</i>. 1991;10(12):918-923.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/1766707/pubmed\" target=\"_blank\" id=\"1766707\">1766707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA, Gilbert DL, and Wolkin AC, &quot;Compatibility of Docetaxel With Selected Drugs During Simulated Y-Site Administration,&quot; <i>Int J Pharmaceut Compound</i>, 1999, 3(3):241-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). <i>Antimicrob Agents Chemother</i>. 2002;46(8):2327-2332.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/12121900 /pubmed\" target=\"_blank\" id=\"12121900 \">12121900 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al, &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, 32(Suppl 20):32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White NJ, &ldquo;Melioidosis,&rdquo; <i>Lancet</i>, 2003, 361(9370):1715-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/12767750/pubmed\" target=\"_blank\" id=\"12767750\">12767750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong VK, Wright HT Jr, Ross LA, et al, &ldquo;Imipenem/Cilastatin Treatment of Bacterial Meningitis in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1991, 10(2):122-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/2062603/pubmed\" target=\"_blank\" id=\"2062603\">2062603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. <i>Pediatr Pulmonol</i>. 2012;47(12):1147-1158.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-pediatric-drug-information/abstract-text/22911974/pubmed\" target=\"_blank\" id=\"22911974\">22911974</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13375 Version 124.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F182065\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F182066\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047840\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442616\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047832\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F182043\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F182027\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047843\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F182059\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047842\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F182095\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F182092\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F182050\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F182031\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299512\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F182036\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F182039\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F182052\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047839\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F182030\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F182049\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1047847\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323195\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F182054\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13375|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">Imipenem and cilastatin: Drug information</a></li><li><a href=\"topic.htm?path=imipenem-and-cilastatin-patient-drug-information\" class=\"drug drug_patient\">Imipenem and cilastatin: Patient drug information</a></li></ul></div></div>","javascript":null}